Aptevo Therapeutics Inc (APVO)

06:31 AM

Aptevo Therapeutics Inc. Stock Analysis and ForecastSuperior trading gains - Autocar Professional

06:31 AM

Jul 19, 2025

What drives Aptevo Therapeutics Inc. stock priceMarket-beating performance - jammulinksnews.com

Jul 19, 2025

Jul 19, 2025

Is Aptevo Therapeutics Inc. a good long term investmentOutstanding investment returns - jammulinksnews.com

Jul 19, 2025

Jul 18, 2025

What analysts say about Aptevo Therapeutics Inc. stockAccelerated profit realization - jammulinksnews.com

Jul 18, 2025

Jul 16, 2025

Aptevo Meets Nasdaq $2.5M Equity Requirement - MSN

Jul 16, 2025

Jul 16, 2025

What makes Aptevo Therapeutics Inc. stock price move sharplyFree Access to Community - Newser

Jul 16, 2025

Jul 15, 2025

Why Aptevo Therapeutics Inc. stock attracts strong analyst attentionFree Elite Traders Group - Newser

Jul 15, 2025

Jul 15, 2025

How Aptevo Therapeutics Inc. stock performs during market volatility2x 3x 5x Pick Alert - Newser

Jul 15, 2025

Jul 11, 2025

10 Best Get Rich Quick Stocks to Buy Now - Insider Monkey

Jul 11, 2025

Jul 02, 2025

Aptevo regains Nasdaq compliance following $15.9 million equity raise By Investing.com - Investing.com India

Jul 02, 2025

Jul 01, 2025

Aptevo Therapeutics Regains Nasdaq Compliance with Equity Raise - TipRanks

Jul 01, 2025

Jul 01, 2025

Aptevo regains Nasdaq compliance following $15.9 million equity raise - Investing.com

Jul 01, 2025

Jun 30, 2025

Aptevo Therapeutics Raises $15.9M to Meet Nasdaq Compliance - TipRanks

Jun 30, 2025

Jun 23, 2025

Aptevo (APVO) appoints Baker Tilly as auditor after Moss Adams merger - Stock Titan

Jun 23, 2025

Jun 22, 2025

Aptevo Therapeutics' 18.7% Plunge: What Drives a Volatile Day Without News? - AInvest

Jun 22, 2025

Jun 21, 2025

Benzinga Bulls And Bears: Circle, Sunrun, JetBlue — And Mideast Has Markets Nervous - Benzinga

Jun 21, 2025

Jun 20, 2025

Aptevo (APVO) appoints Baker Tilly as auditor after Moss Adams merger | C SEC FilingForm 424B2 - Stock Titan

Jun 20, 2025

Jun 19, 2025

Aptevo Therapeutics Surges 82% Amid No Fundamental News—What’s Driving the Spike? - AInvest

Jun 19, 2025

Jun 18, 2025

Top Small Cap Stocks Worth WatchingJune 18th - MarketBeat

Jun 18, 2025

Jun 18, 2025

Crude Oil Moves Higher; US Weekly Jobless Claims Decline - Benzinga

Jun 18, 2025

Jun 18, 2025

Aptevo Therapeutics raises $8 million in registered direct offering - Investing.com Australia

Jun 18, 2025

Jun 18, 2025

Dow Surges 150 Points; Korn Ferry Earnings Top Views - Benzinga

Jun 18, 2025

Jun 18, 2025

Aptevo Therapeutics (APVO) Secures $8M Through Direct Offering - GuruFocus

Jun 18, 2025

Jun 18, 2025

Aptevo Therapeutics announces $8M at-the-market equity offering with warrants; shares more than double - MSN

Jun 18, 2025

Jun 18, 2025

Aptevo Therapeutics raises $8 million in registered direct offering By Investing.com - Investing.com India

Jun 18, 2025

Jun 18, 2025

Why Is Micro-Cap Aptevo Stock Trading Higher On Wednesday?Aptevo Therapeutics (NASDAQ:APVO) - Benzinga

Jun 18, 2025

Jun 18, 2025

Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules | APVO Stock News - GuruFocus

Jun 18, 2025

Jun 18, 2025

An early stage 85% remissions rate in AML drives Aptevo’s stock surge - BioWorld MedTech

Jun 18, 2025

Jun 18, 2025

Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules - ACCESS Newswire

Jun 18, 2025

Jun 18, 2025

Aptevo Secures $8M Funding: Biotech Company Accelerates Cancer Drug Development Pipeline - Stock Titan

Jun 18, 2025

Jun 18, 2025

Aptevo Therapeutics stock soars after impressive AML treatment results - Investing.com

Jun 18, 2025

Jun 18, 2025

Aptevo Therapeutics stock soars after impressive AML treatment results By Investing.com - Investing.com Canada

Jun 18, 2025

Jun 18, 2025

Why did Aptevo Therapeutics Shares Skyrocket in Premarket Trading Today? - Tokenist

Jun 18, 2025

Jun 18, 2025

Aptevo Therapeutics Skyrockets on Game-Changing AML Drug News - RagingBull

Jun 18, 2025

Jun 18, 2025

Aptevo reports 85% remission rate in frontline AML trial By Investing.com - Investing.com Nigeria

Jun 18, 2025

Jun 18, 2025

Aptevo Therapeutics (APVO) Shows Promising Results in RAINIER Tr - GuruFocus

Jun 18, 2025

Jun 18, 2025

Aptevo Says Its Mipletamig Therapy Achieves 85% Remission Rate in Leukemia Patients; Shares Soar Pre-Bell - MarketScreener

Jun 18, 2025

Jun 18, 2025

Aptevo Therapeutics (APVO) Shows Promising Results in AML Trial - GuruFocus

Jun 18, 2025

Jun 18, 2025

Aptevo Therapeutics announces new clinical data from RAINIER trial - TipRanks

Jun 18, 2025

Jun 18, 2025

Aptevo announces clinical data from ongoing Phase 1b/2 RAINIER trial - TipRanks

Jun 18, 2025

Jun 18, 2025

Breakthrough AML Drug Achieves 85% Remission Rate: New Hope for Previously Untreatable Patients - Stock Titan

Jun 18, 2025

Jun 18, 2025

Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML | APVO Stock News - GuruFocus

Jun 18, 2025

Jun 17, 2025

Aptevo Therapeutics Signs Equity Purchase Agreement - TipRanks

Jun 17, 2025

Jun 16, 2025

APVO Secures Roth Capital Partners as Exclusive Placement Agent - GuruFocus

Jun 16, 2025

Jun 15, 2025

Short Interest in Aptevo Therapeutics Inc. (NASDAQ:APVO) Decreases By 55.0% - Defense World

Jun 15, 2025

Jun 14, 2025

Aptevo Stock Rises On $2.1M Registered Direct Offering, Warrant Sale: Retail Sentiment Touches Year-High - MSN

Jun 14, 2025

Jun 13, 2025

Aptevo Participating in the BIO International Convention | APVO Stock News - GuruFocus

Jun 13, 2025